肺低形成症の再生療法としての連続羊水注入
子宮内腎不全または重度の腎異常を伴う胎児の肺機能不全に対する再生療法としての連続羊水注入 - 実現可能性研究
Congenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to the lack of amniotic fluid. Survivors have significant risk of renal impairment (90%) requiring dialysis or renal transplantation if no fetal intervention is performed.
Renal agenesis is the congenital absence of one or both kidneys due to complete failure of the kidney to form. As many as 33% of fetuses with bilateral renal agenesis are stillborn, and the rest of them die immediately after birth due to severe pulmonary hypoplasia.
The objective of the serial amnioinfusions for fetuses with these conditions will be to reduce the severity of pulmonary hypoplasia (regenerating the lung functionality) and therefore increase the chance that the newborn survives to begin peritoneal dialysis. Although there is initial evidence that serial amnioinfusions are feasible for the pregnant women and the fetuses, there is still a need to have a prospective clinical trial to confirm the hypothesis that serial amnioinfusions could prevent severe pulmonary hypoplasia allowing the newborns with bilateral renal agenesis or severe LUTO to survive to begin peritoneal dialysis.
Therefore, the investigators aim to study the hypothesis that serial amnioinfusions for fetuses with severe LUTO and renal failure and those with bilateral renal agenesis will reduce the severity of pulmonary hypoplasia and therefore increase the chance that the newborn survives to begin peritoneal dialysis.
調査の概要
詳細な説明
All women with fetuses having either severe LUTO with intrauterine renal failure or bilateral renal agenesis that meet the inclusion criteria will be invited to participate in this study. For those patients, the actual standard of care is expectant prenatal management or termination of pregnancy (<22 weeks according to law). This study will offer serial amnioinfusions for patients with LUTO or bilateral renal agenesis. Due to the rarity and complexity of these cases, the investigators expect to enroll a maximum of 5 women with affected fetuses per year. After two years (approximately 10 cases), a review of the data will be completed including all outcomes to determine whether to continue towards the original goal of treating 40 patients (20 mothers with affected fetuses) or to close the study,.
All procedures are anticipated to take place in the Family Birth Center at Mayo Clinic, Rochester. Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks. This procedure will be performed in a sterile fashion within the operating room using the same technique that is routinely used to perform the ultrasound-guided amnioinfusion. Once consented, weekly ultrasound monitoring will be conducted and if the amniotic fluid index (AFI) is determined to be <2 cm, amnioinfusion will proceed. Prior to each infusion, 5mLs of amniotic fluid will be collected to study surrogate markers of lung function (research only). Using a 22-gauge needle, warm sterile lactated ringer solution will be infused into the amniotic cavity until the AFI is equal to 8 cm. Some studies have demonstrated that the composition of the amniotic fluid during second and third trimester is closer to the lactated ringer solution. This procedure will be continued weekly until the fetus reaches 34 weeks, after which only monitoring will occur. If preterm premature rupture of the membranes (PPROM) occurs prior to 34 weeks, no further amnioinfusion procedures will be performed. Patients with PPROM will be managed according to the standardized clinical management. The anticipated length of stay in the hospital after each infusion is approximately 2 days if no uterine contractions are observed.
The prenatal care, delivery and postnatal management of the infant will be conducted according to the standardized clinical care. Delivery will be scheduled at the Mayo Clinic Family Birth Center and the infants will be followed for 24 months by the multi-specialty team as part of the standard clinical management including follow-up with neonatologist (NICU team), pediatric nephrology and transplant team according to the clinical protocol for postnatal renal replacement therapy and transplant. Neurodevelopment of the children will assessed using a combination of clinical examination and the Bayley Scale of Infant Development during the first 24 months of life.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前：Taylor M Rasmusson, MSN
- 電話番号：507-266-4813
- メール：Rasmusson.Taylor@mayo.edu
研究連絡先のバックアップ
- 名前：Jainnee McCann
- 電話番号：507-538-5679
- メール：McCann.Jainnee@mayo.edu
研究場所
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic
-
主任研究者：
- Mauro Schenone, MD
-
コンタクト：
- Maureen A Lemens, BSN, RN
- 電話番号：507.293.1487
- メール：lemens.maureen@mayo.edu
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Pregnant women with singleton uterine pregnancy
- Maternal age > age 18
- Fetus < 26 weeks gestational age with severe LUTO and intrauterine renal failure
- Fetus < 26 weeks gestational age with bilateral renal agenesis
- Fetus with absence of chromosome abnormalities
- Fetus with absence of associated anomalies
- Mother has negative Hepatitis B, Hepatitis C, and HIV testing
- Mother meets psychosocial criteria that allows her to make a conscious decision about her fetus/infant
Exclusion Criteria:
- Associated fetal anomaly unrelated to LUTO or renal agenesis
- Increased risk for preterm labor including short cervical length, history of incompetent cervix with or without cerclage, and previous preterm birth
- Placental abnormalities known at time of enrollment
- Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy
- Maternal medical condition that is a contraindication to surgery or anesthesia
- Mother has declined invasive testing
- Inability to comply with the travel and follow-up requirements of the trial
- Participation in another interventional study that influences maternal and fetal morbidity and mortality
- Participation in this clinical trial during a previous pregnancy
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Amnioinfusion
Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks. |
Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Adverse Events
時間枠：First amnioinfusion through delivery which may be up to 22 weeks.
|
Total number of Adverse Events experienced |
First amnioinfusion through delivery which may be up to 22 weeks.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Survival to renal transplant
時間枠：5 years
|
Number of subjects able to receive renal transplant. |
5 years
|
|
Survival to dialysis
時間枠：From time of birth up to one month
|
Number of subjects able to receive dialysis |
From time of birth up to one month
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Mauro Schenone, MD、Mayo Clinic
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 17-007726
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。